PARP inhibitor use linked to MDS, AML risk

Key clinical point: Poly (ADP-ribose) polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Major finding: Meta-analysis of 18 placebo randomized clinical trials (n=7,307) revealed an increased risk for MDS and AML with PARP inhibitors vs. placebo (Peto odds ratio, 2.63; P = .026). The incidence of MDS and AML across PARP inhibitor groups was 0.73% vs. 0.47% for placebo groups. In VigiBase, median treatment duration was 9.8 months and median latency period since first exposure to a PARP inhibitor was 17.8 months. Of 104 cases of MDS/AML that reported outcomes, 45% of cases resulted in death.

Study details: This study estimated the risk of MDS and AML related to PARP inhibitors, via a systematic review and safety meta-analysis, and described clinical features of PARP inhibitor-related MDS (n = 99) and AML (n = 79) cases reported in VigiBase, the WHO’s pharmacovigilance database.

Disclosures: The study did not receive any funding. Some study investigators reported receiving grants and personal fees from various pharmaceutical companies outside the submitted work.

Source: Morice PM et al. Lancet Haematol. 2020 Dec 18. doi: 10.1016/S2352-3026(20)30360-4.

Key clinical point: Poly (ADP-ribose) polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Major finding: Meta-analysis of 18 placebo randomized clinical trials (n=7,307) revealed an increased risk for MDS and AML with PARP inhibitors vs. placebo (Peto odds ratio, 2.63; P = .026). The incidence of MDS and AML across PARP inhibitor groups was 0.73% vs. 0.47% for placebo groups. In VigiBase, median treatment duration was 9.8 months and median latency period since first exposure to a PARP inhibitor was 17.8 months. Of 104 cases of MDS/AML that reported outcomes, 45% of cases resulted in death.

Study details: This study estimated the risk of MDS and AML related to PARP inhibitors, via a systematic review and safety meta-analysis, and described clinical features of PARP inhibitor-related MDS (n = 99) and AML (n = 79) cases reported in VigiBase, the WHO’s pharmacovigilance database.

Disclosures: The study did not receive any funding. Some study investigators reported receiving grants and personal fees from various pharmaceutical companies outside the submitted work.

Source: Morice PM et al. Lancet Haematol. 2020 Dec 18. doi: 10.1016/S2352-3026(20)30360-4.

Key clinical point: Poly (ADP-ribose) polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Major finding: Meta-analysis of 18 placebo randomized clinical trials (n=7,307) revealed an increased risk for MDS and AML with PARP inhibitors vs. placebo (Peto odds ratio, 2.63; P = .026). The incidence of MDS and AML across PARP inhibitor groups was 0.73% vs. 0.47% for placebo groups. In VigiBase, median treatment duration was 9.8 months and median latency period since first exposure to a PARP inhibitor was 17.8 months. Of 104 cases of MDS/AML that reported outcomes, 45% of cases resulted in death.

Study details: This study estimated the risk of MDS and AML related to PARP inhibitors, via a systematic review and safety meta-analysis, and described clinical features of PARP inhibitor-related MDS (n = 99) and AML (n = 79) cases reported in VigiBase, the WHO’s pharmacovigilance database.

Disclosures: The study did not receive any funding. Some study investigators reported receiving grants and personal fees from various pharmaceutical companies outside the submitted work.

Source: Morice PM et al. Lancet Haematol. 2020 Dec 18. doi: 10.1016/S2352-3026(20)30360-4.